TOSCA

Three Or Six Colon Adjuvant

A RANDOMIZED TRIAL INVESTIGATING THE ROLE OF FOLFOX-4 OR XELOX (3 VERSUS 6 MONTHS) REGIMEN DURATION AND BEVACIZUMAB AS ADJUVANT THERAPY FOR PATIENTS WITH STAGE II/III COLON CANCER

ASCO CONGRESS 2019

Annual Meeting

Scarica il file 

Scarica il file 

ESMO CONGRESS 2019

BARCELONA 27 settembre 01 ottobre 2019

Scarica il file 

Scarica il file 

AIOM CONGRESS 2019

Congresso Nazionale

Scarica il file 

Scarica il file  

ABSTRACT XX

Congresso Nazionale AIOM 2018

ROMA 16 - 17 - 18 novembre 2018

Scarica il file 

Scarica il file 

Scarica il file  

· DURATION OF OXALIPLATIN - CONTAINING ADJUVANT.

  THERAPY FOR STAGE III COLON CANCER: ASCO CLINICAL PRACTICE GUIDELINE

Scarica il file  

· IMPACT OF METFORMIN USE AND DIABETIC STATUS DURING ADJUVANT FLUOROPYRIMIDINE -

  OXALIPLATIN CHEMOTHERAPY ON THE OUTCOME OF PATIENTS WITH RESECTED COLON CANCER:

  A TOSCA STUDY SUBANALYSIS

Scarica il file  

· TOSCA IDEA: RIFLESSIONI E COMMENTI

Scarica il file  

· NEWSLETTER

Scarica il file  

· FOLFOX OR CAPOX IN STAGE II TO III COLON CANCER: EFFICACY RESULTS OF THE ITALIAN THREE

  OR SIX COLON ADJUVANT TRIAL

Scarica il file  

· THE HARD ROAD TO DATA INTERPRETATION: THREE OR SIX MONTHS OF ADJUVANT

  CHEMOTHERAPIE FOR PATIENTS WITH STAGE III COLON CANCER?

Scarica il file  

· DURATION OF ADJUVANT CHEMOTHERAPY FOR STAGE III COLON CANCER

Scarica il file  

· PHASE III TRIAL COMPARING 3-6 MONTHS OF ADJUVANT FOLFOX4/XELOX IN STAGE II-III COLON     CANCER: SAFETY AND COMPLIANCE IN THE TOSCA TRIAL

Scarica il file  

· GENETIC MARKERS FOR TOXICITY OD ADJUVANT OXALIPLATIN AND FLUOROPYRIMIDINES IN THE   PHASE III TOSCA TRIAL IN HIGH-RISK COLON CANCER PATIENTS

Scarica il file  

· DIHYDROPYRIMIDINE DEHYDROGENASE PHARMACOGENETICS FOR PREDICTING  

  FLUOROPYRIMIDINE-RELATED TOXICITY IN THE RANDOMIZED, PHASE III ADJUVANT TOSCA TRIAL

  IN HIGH-RISK COLON CANCER PATIENTS

· ABSTRACT ASCO 2017 - ORAL PRESENTATION

Scarica il file  

Scarica il file  

FONDAZIONE
GISCAD

GRUPPO ITALIANO PER LO STUDIO DEI 

CARCINOMI DELL'APPARATO DIGERENTE

SEDE

Via Gattinoni, 4

20010 Vanzago (MI)

CONTATTI

Tel. 02 84968409

ufficio.operativo@giscad.it

© 2018 Fondazione GISCAD - P.IVA 05396970963